Comparison of variables associated with cerebrospinal fluid neurofilament, total-tau, and neurogranin.
Autor: | Mielke MM; Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Electronic address: Mielke.Michelle@mayo.edu., Syrjanen JA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL (H.Z.), London, UK., Skoog I; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden., Vemuri P; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Machulda MM; Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA., Graff-Radford J; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Knopman DS; Department of Neurology, Mayo Clinic, Rochester, MN, USA., Jack CR Jr; Department of Radiology, Mayo Clinic, Rochester, MN, USA., Petersen RC; Department of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA., Kern S; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden. |
---|---|
Jazyk: | angličtina |
Zdroj: | Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2019 Nov; Vol. 15 (11), pp. 1437-1447. Date of Electronic Publication: 2019 Oct 23. |
DOI: | 10.1016/j.jalz.2019.07.009 |
Abstrakt: | Introduction: Three cerebrospinal fluid (CSF) markers of neurodegeneration (N) (neurofilament light [NfL], total-tau [T-tau], and neurogranin [Ng]) have been proposed under the AT(N) scheme of the National Institute on Aging-Alzheimer's Association Research Framework. Methods: We examined, in a community-based population (N = 777, aged 50-95) (1) what variables were associated with each of the CSF (N) markers, and (2) whether the variables associated with each marker differed by increased brain amyloid. CSF T-tau was measured with an automated electrochemiluminescence Elecsys immunoassay; NfL and Ng were measured with in-house enzyme-linked immunosorbent assays. Results: Multiple variables were differentially associated with CSF NfL and T-tau levels, but not Ng. Most associations were attenuated after adjustment for age and sex. T-tau had the strongest association with cognition in the presence of amyloidosis, followed by Ng. Variables associations with NfL did not differ by amyloid status. Discussion: Understanding factors that influence CSF (N) markers will assist in the interpretation and utility of these markers in clinical practice. (Copyright © 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |